ARMIDA LABS, INC.
SAN DIEGO, CA
What changed
NIH R44 · $1.2M · Targeting pancreatic cancer metastases with Targefrin
10mo agoGrant renewalSep 10, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 25 out of 100, unchanged since the last recompute.
Little recent filing activity, or the events on file have decayed.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
12,339 pre-ticker oncology companies at Grant-only
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
R44 · $1.2M · non-dilutive
Apr 30, 2024ARMIDA LABS, INC. · PI BAGGIO, CARLO · NCI · award ends Aug 31, 2027 · Targeting pancreatic cancer metastases with Targefrin
NIH RePORTER · NIH RePORTER 11256224 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources